key: cord-0708590-0vtazttz
authors: Egron, Carole; Roszyk, Laurence; Rochette, Emmanuelle; Jabaudon, Matthieu; Sapin, Vincent; Mulliez, Aurélien; Labbé, André; Coste, Karen
title: Serum soluble receptor for advanced glycation end‐products during acute bronchiolitis in infant: Prospective study in 93 cases
date: 2018-08-16
journal: Pediatr Pulmonol
DOI: 10.1002/ppul.24141
sha: 6a47313d7fb53f6fa7fe4834df9bb80636458dfc
doc_id: 708590
cord_uid: 0vtazttz

INTRODUCTION: Acute bronchiolitis is a major cause of acute respiratory distress in infants. The soluble receptor for advanced glycation end‐products (sRAGE) is a biomarker of pulmonary damage processes, with a diagnostic and a prognostic value in acute respiratory distress syndrome (ARDS). The RAGE pathway is also implicated in the pathogenesis of other respiratory diseases like asthma, but the value of sRAGE levels in acute bronchiolitis remains under‐investigated. MATERIAL AND METHODS: A prospective, observational, and analytical study was conducted at Clermont‐Ferrand University Hospital. The main objective was to evaluate the correlation between serum sRAGE and clinical severity of bronchiolitis in hospitalized infants aged <1 year. We analyzed correlations between serum sRAGE and Wainwright score, short‐term morbidity attributable to bronchiolitis, causal viruses and risk for recurrent wheezing at 1 year. RESULTS: The study included 93 infants. sRAGE levels were significantly lower in acute bronchiolitis patients (mean 1101 pg/mL) than in controls (2203 pg/mL, P < 0.001) but did not correlate with clinical severity. No correlation was found between serum sRAGE and severity score, respiratory viruses, and recurrent wheezing at 1 year. Serum sRAGE levels were negatively correlated with age (r = −0.45, P < 0.001). CONCLUSION: Serum sRAGE levels are decreased in acute bronchiolitis but not correlated with disease severity. sRAGE levels should be age‐adjusted in infants. Serum sRAGE levels measured in the setting of acute bronchiolitis were not predictive of recurrent wheezing.

role for RAGE in lung diseases such as asthma, allergic airway inflammation, acute respiratory distress syndrome (ARDS) or bronchopulmonary dysplasia. 9 Soluble RAGE (sRAGE) represents the total pool of soluble forms of RAGE that can be measured in the extracellular compartment (eg, in biological fluids). sRAGE lacks the transmembrane domain by alternative splicing mechanisms or through proteolytic cleavage, 10 but includes the extracellular domain of mRAGE. Thus, sRAGE acts as a decoy to prevent the activation of mRAGE by ligands and its proinflammatory action 10 (Figure 1 ).

Several human studies argue that sRAGE is a marker of pulmonary damage processes. In both adults and children, plasma sRAGE is associated with severity and prognosis of ARDS. [11] [12] [13] sRAGE measurements may also be valuable for assessing the severity of asthma in children. 14, 15 However, the value of measuring sRAGE during acute bronchiolitis has been poorly investigated to date. 16 We designed this study to investigate whether serum sRAGE could be a marker of severity in infants with acute bronchiolitis and a predictor of risk for the development of recurrent wheezing. Bronchiolitis was diagnosed by the presence of a recent history of upper FIGURE 1 sRAGE arises by alternative splicing mechanisms or through proteolytic cleavage. sRAGE includes the extracellular domain of mRAGE. In the extracellular compartment, sRAGE acts as a decoy by capturing mRAGE receptor ligands and blocking its pro-inflammatory signal respiratory tract infection followed by onset of respiratory distress with cough, tachypnea, retraction and auscultatory findings of diffuse crackles or wheezes, in accordance with international recommendations on the diagnosis and management of acute bronchiolitis. 17 Admission criteria were based on French national guidelines. 18 Pediatric intensive care unit (PICU) was needed in case of signs of exhaustion such as listlessness or decreased respiratory effort, recurrent apnea, or failure to maintain adequate oxygen saturation despite oxygen supplementation. 19 Infants born before 34 weeks of amenorrhea or infants with cystic fibrosis, bronchopulmonary dysplasia, suspected primary ciliary dyskinesia, congenital heart disease, immune deficiency, or acute renal failure were excluded.

Infants aged <1 year attending an anesthesia consultation ahead of planned surgical intervention were enrolled as control group. Health status was evaluated by a complete medical check-up, with a clinical questionnaire. Children with a previous history of pulmonary disease (history of wheezing, cardiopulmonary disease, chronic pulmonary disease or prematurity) or with an infectious process were excluded.

Cases and controls were enrolled after providing the parents oral and written information and collecting their written consent.

Clinical severity was assessed at inclusion using the Wainwright clinical score and was based on respiratory effort, oxygen saturation, and respiratory rate. This score defines three stages of severity: non-severe bronchiolitis, moderate, or severe. 20 Other data collected included personal medical history (perinatal and atopic history), immediate complications related to acute bronchiolitis (bacterial superinfection, pneumothorax, atelectasis) and use of oral or inhaled corticosteroids.

Immediate morbidity and mortality were assessed using data collected during hospitalization: length of hospital stay, use and durations of enteral nutrition or parenteral rehydration, need for oxygen therapy or respiratory support (continuous positive airway pressure [CPAP] or bi-level positive airway pressure [BiPAP]) or invasive mechanical ventilation, incidence of superinfection as diagnosed biologically or radiologically, radiographic features of ventilation disorder or radiologically-documented gas effusion, bronchospasm, use of inhaled beta-agonists or corticosteroids, and death.

Families were phone-surveyed at 30 days and 1 year after inclusion to collect data on recurrence of wheezing (bronchiolitis, asthma, wheezing without consultation) and use of respiratory treatments (oral corticosteroids, respiratory physiotherapy, hospital admissions for respiratory reasons). The diagnosis of recurrent wheezing, if not already established by another pediatrician, was based on occurrence of a third bronchiolitis episode or prescription of a long-term treatment for respiratory symptoms.

At admission to hospital, blood samples (2.5 mL) was sampled by venipuncture into VACUETTE® tubes with lithium heparin, and urine (2 mL) was sampled into VACUETTE® Z tubes without additive by collecting pockets or compresses in the layer. Blood and urine samples were immediately centrifuged at 2500 rpm for 15 min, and the supernatants were kept frozen at −80°C until analysis. sRAGE levels were measured in duplicate using purpose-designed commercially-available ELISA kits (RAGE Quantikine, R&D Systems, Minneapolis, MN) with a manufacturer-stated limit of detection of 78 pg/mL. The personnel responsible for performing sRAGE assays had no knowledge of the clinical setting.

Nasopharyngeal swab samples were collected by aspiration of nasal secretion. Viral analysis was carried out using enzymatic immunoassay chromatography for RSV antigen detection. Molecular biology methods included reverse transcription-polymerase chain reaction (RT-PCR) for RSV and rhinovirus in infants admitted to general pediatric and short-stay units, and a multiplex PCR panel (adenovirus, coronavirus, metapneumovirus, enterovirus/rhinovirus, influenza A and B, parainfluenza virus, RSV, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae) in infants admitted to the intensive care unit. Rhinovirus strains were genotyped. Chest X-ray was performed only when respiratory complications and/or recurrent wheezing were suspected.

All statistical analyses were performed using Stata 13 (StataCorp, College Station, TX) with a P-value of <0.05 (two-sided) considered statistically significant. Data were expressed as frequencies and percentages for qualitative variables and as means and standard deviations or medians and interquartile intervals for quantitative variables.

The case-control analysis was performed using the χ 2 test (or 

Ninety-three cases were included. They were mainly young infants, with a median age of 1.8 (0.9-3.5) months. Most had a first (n = 83, 89%) mild (n = 67, 72%) episode of acute bronchiolitis, 20 (22%) cases had a moderate episode, and 6 (7%) presented a severe acute bronchiolitis according to Wainwright score. Median hospital stay was 4 (3-6) days and was significantly associated with Wainwright score, with a median stay of 3 (2-5) days for non-severe bronchiolitis, 7.5 (5.5-10) days for moderate bronchiolitis, and 8 (7-10) days for severe bronchiolitis (P < 0.001). Twentyfive infants were admitted to the intensive care unit, including eight cases admitted for apnea (Table 1) . None developed ARDS.

Fifty-five percent of cases had a first-degree family history of atopic disease and 27% a family history of asthma. Fifteen percent of cases had a personal history of atopic diseases: 11% had eczema, 1% had cow's milk protein allergy, and 4% had recurrent wheezing at study inclusion (three cases were enrolled at their third episode, and one case included was enrolled during his fourth episode). Bronchial crackles were found in 42% of children. Eight percent were treated with betaagonists and 5% with inhaled corticosteroids.

One year after inclusion, 85 (91%) parents of cases responded to our phone survey: 37 (44%) infants developed recurrent wheezing.

Thirty-two controls were included, with a median age of 6.3 (2.7-9.3) months (P = 0.012, when age-compared against cases). Most were boys (72%), but the gender difference between case and control populations was not statistically significant (P = 0.06). There was no difference between case and control groups on birth term (P = 0.45) and weight (P = 0.79).

Mean serum sRAGE was 1103 (SD: 0.654) pg/mL in infants with acute bronchiolitis. Mean serum sRAGE correlated negatively with age (r = −0.45, P < 0.001), with the highest rates found among younger infants ( Table 2 ). This correlation was confirmed in multivariate analysis (P < 0.001). Mean serum sRAGE was 2.203 (SD: 0.905) pg/mL in controls, with no statistically significant correlation with age (r = −0.32, P = 0.07, Table 2 ). Serum sRAGE levels were significantly higher in controls than in infants with acute bronchiolitis (P < 0.001), even after multivariate adjustment including age as a covariate (P < 0.001, Figure 2 ). The multivariate analysis showed a lowered attrition rate of 1.382 points in cases, and each additional month of life lowered the attrition rate by 86.6 points. sRAGE levels did not differ according to causal virus. sRAGE was undetected in all urine samples. Patients with complications such as bacterial superinfection (P = 0.35) or atelectasis (P = 0.31) had similar sRAGE levels to those who did not. 

The main objective of this study was to investigate the association between serum sRAGE and severity of acute bronchiolitis in Bacterial superinfection 16 17 which could also be surprising. Additionally, there was no correlation between sRAGE rates and severity as evaluated by morbidity data such as total hospital stay, type of hospital unit, the need for respiratory support, or respiratory support duration. These morbidity data are probably even more reliable than the Wainwright score since evaluated once at inclusion of cases. The low number of severe cases could be a bias in our study, and this seems true according to the distribution of our population established on the Wainwright score.

However, when we observe the severity on hospitalization data, 25

cases were admitted to the intensive care unit, representing the real most severe cases of acute bronchiolitis.

To explain low serum sRAGE levels during acute bronchiolitis, two physiopathological hypotheses can be made. It has been supposed that high sRAGE levels could exert beneficial anti-inflammatory effects by blocking the pro-inflammatory axis of RAGE. 6, 21 If sRAGE is considered as a "blocker" of the inflammatory cascade, it could be "consumed" by its binding with pro-inflammatory RAGE ligands in order to control the inflammation generated by viral aggression. It could partly explain the lower sRAGE levels in the bronchiolitis group than in the control group here. On the other hand, it may be hypothesized that constitutive lower sRAGE levels predispose for acute bronchiolitis and severe episodes. But the results of this first observational study must be confirmed by larger and more multicentric populations before concluding a physiopathological model. A cohort study from birth, with measured sRAGE kinetics could arbitrate between a predisposing role or a post-event consequence of lower sRAGE levels in acute bronchiolitis.

Regardless, the relationship between sRAGE and the severity of acute bronchiolitis cannot be interpreted without consideration of age.

Indeed, a singular feature of sRAGE levels in infancy is broad variability with age due to pulmonary maturation and alveolarization processes that last up to 12-24 months. 6,22 sRAGE levels decrease progressively in the bronchoalveolar fluid (BALF) and serum from 30 weeks of amenorrhea to birth and again from birth to adulthood. 23, 24 Our findings confirm this and are well described in Figure 2 . Unfortunately, we did not obtain data in control infants under one month old, so our study may be underpowered to detect significant negative correlation between serum sRAGE and age in controls. This major variation factor of sRAGE levels could explain the discrepancies in the study results of García-Salido et al. 16 Their study showed a pattern opposite from ours, that is, higher serum sRAGE levels in severe acute bronchiolitis than in controls. This different pattern seems likely due to control-group factors, as García-Salido et al controls were older than the target population for acute bronchiolitis with an average age of 8 years (14 This large-cohort study found that serum sRAGE levels were lower in infants with acute bronchiolitis than without acute bronchiolitis, whatever their ages. Finally, our study does not show any difference in sRAGE levels according to acute bronchiolitis severity, even after adjusting for age. In our study, age was a major confounding factor for acute bronchiolitis severity (the more severe are the youngest) and sRAGE physiological levels (higher rates are found in the youngest).

After age adjustment, sRAGE rates seem more related to the presence or absence of acute bronchiolitis rather than to its severity. In the long term, sRAGE levels did not correlated with risk for recurrent wheezing at 1 year.

Pertinence du recours à l'hospitalisation pour bronchiolite (GHM 04M18)

In very young infants severity of acute bronchiolitis depends on carried viruses

Ten years of human metapneumovirus research

Understanding RAGE, the receptor for advanced glycation end products

Receptor for advanced glycation end-products is a marker of type I lung alveolar cells

The receptor for advanced glycation end products (RAGE) and the lung

Overexpression of RAGE Contributes to Cigarette Smoke-Induced Nitric Oxide Generation in COPD

The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?

All the "RAGE" in lung disease: the receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses

Circulating HMGB1 and RAGE as clinical biomarkers in malignant and autoimmune diseases

Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of severe sepsis in critically ill patients

Circulating markers of endothelial and alveolar epithelial dysfunction are associated with mortality in pediatric acute respiratory distress syndrome

Elevated plasma levels of sRAGE are associated with nonfocal CT-Based lung imaging in patients with ARDS: a prospective multicenter study

Serum level of soluble receptor for advanced glycation end products in asthmatic children and its correlation to severity and pulmonary functions

Fraction of exhaled nitric oxide and soluble receptors for advanced glycation end products are negatively correlated in children with recurrent wheezing

Serum sRAGE as a potential biomarker for pediatric bronchiolitis: a pilot study

American academy of pediatrics subcommittee on diagnosis and management of bronchiolitis. diagnosis and management of bronchiolitis

National Collaborating Centre for Women's and Children's Health (UK). Bronchiolitis: Diagnosis and Management of Bronchiolitis in Children. London: National Institute for Health and Care Excellence (UK)

A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis

Archives De Pédiatrie: Organe Officiel De La Sociéte Française De Pédiatrie

RAGE controls leukocyte adhesion in preterm and term infants

Soluble receptor for advanced glycation end products (sRAGE) is present at high concentrations in the lungs of children and varies with age and the pattern of lung inflammation

Circulating soluble RAGE and cell surface RAGE on peripheral blood mononuclear cells in healthy children

Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection

Serum soluble receptor for advanced glycation end-products during acute bronchiolitis in infant: Prospective study in 93 cases

The authors thank Pr Cécile Henquel and her team at the Clermont- 

None.

http://orcid.org/0000-0001-5832-3572